Analysts expect Revolution Medicines, Inc. to report revenue of 414.11 M for Q4 26, against a range of 392.29 M to 435.93 M. The most recent reported quarter, Q3 26, came in at 197.60 M, a 727.0% beat against the 23.89 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 197.60 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 409,245.49 | 0.00 | 31.56 M | 1.65 M | 3.67 M | 2.65 M | 1.75 M | 26.24 M | 435.93 M | 446.44 M | 596.96 M | 672.16 M | 686.07 M | 729.23 M | 799.68 M | 887.03 M | |||||||||
| Low Estimate | 361,814.51 | 0.00 | 26.26 M | 1.50 M | 3.32 M | 2.34 M | 1.55 M | 21.55 M | 392.29 M | 412.97 M | 514.86 M | 560.11 M | 621.70 M | 619.82 M | 689.90 M | 834.30 M | |||||||||
| Consensus Estimate | 385,530.00 | 0.00 | 28.91 M | 1.57 M | 3.50 M | 2.49 M | 1.65 M | 23.89 M | 414.11 M | 429.71 M | 555.91 M | 616.13 M | 653.88 M | 674.53 M | 744.79 M | 860.66 M |
Analysts expect Revolution Medicines, Inc. to report earnings per share of -1.18 for Q4 26, against a range of -1.22 to -1.14. The most recent reported quarter, Q3 26, came in at -1.90, a 13.6% beat against the -2.20 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.12 | -1.13 | -1.31 | -1.61 | -1.86 | -2.29 | -3.06 | -1.90 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -0.98 | -0.94 | -1.01 | -1.25 | -1.44 | -1.82 | -1.85 | -2.05 | -1.14 | -0.74 | -0.59 | -0.45 | -0.29 | -0.12 | -0.05 | 0.41 | |||||||||
| Low Estimate | -1.12 | -1.10 | -1.17 | -1.49 | -1.64 | -2.04 | -2.09 | -2.35 | -1.22 | -0.86 | -0.67 | -0.49 | -0.33 | -0.14 | -0.05 | 0.35 | |||||||||
| Consensus Estimate | -1.05 | -1.02 | -1.09 | -1.37 | -1.54 | -1.93 | -1.97 | -2.20 | -1.18 | -0.80 | -0.63 | -0.47 | -0.31 | -0.13 | -0.05 | 0.38 |
Pull Wall Street consensus for Revolution Medicines, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=RVMDW&mode=revenue&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "RVMDW", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/estimates?ticker=RVMDW&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();